Literature DB >> 27240055

Monitoring immune responses in the tumor microenvironment.

Jennifer A Wargo1, Sangeetha M Reddy2, Alexandre Reuben3, Padmanee Sharma4.   

Abstract

Immune monitoring in the tumor microenvironment allows for important insights into immune mechanisms of response and resistance to various cancer treatments; however clinical challenges exist using current strategies. Significant questions remain regarding monitoring of archival versus fresh tissue, assessment of static versus dynamic markers, evaluation of limited tissue samples, and the translation of insights gained from immunologically 'hot' tumors such as melanoma to other 'cold' tumor microenvironments prevalent in other cancer types. Current and emerging immune monitoring strategies will be examined herein, and genomic-based assays complementing these techniques will also be discussed. Finally, host genomic and external environmental factors influencing anti-tumor immune responses will be considered, including the role of the gut microbiome. Though optimal immune monitoring techniques are in evolution, great promise exists in recent advances that will help guide patient selection as far as type, sequence, and combination of therapeutic regimens to enhance anti-tumor immunity and clinical responses.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27240055      PMCID: PMC5257261          DOI: 10.1016/j.coi.2016.05.006

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  63 in total

1.  Direct multiplexed measurement of gene expression with color-coded probe pairs.

Authors:  Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov
Journal:  Nat Biotechnol       Date:  2008-02-17       Impact factor: 54.908

Review 2.  Membrane vesicles as conveyors of immune responses.

Authors:  Clotilde Théry; Matias Ostrowski; Elodie Segura
Journal:  Nat Rev Immunol       Date:  2009-06-05       Impact factor: 53.106

3.  Association of CTLA-4 polymorphisms with improved overall survival in melanoma patients treated with CTLA-4 blockade: a pilot study.

Authors:  P Queirolo; A Morabito; S Laurent; S Lastraioli; P Piccioli; P A Ascierto; G Gentilcore; M Serra; A Marasco; E Tornari; B Dozin; M P Pistillo
Journal:  Cancer Invest       Date:  2013-05-03       Impact factor: 2.176

Review 4.  Highly multiparametric analysis by mass cytometry.

Authors:  Olga Ornatsky; Dmitry Bandura; Vladimir Baranov; Mark Nitz; Mitchell A Winnik; Scott Tanner
Journal:  J Immunol Methods       Date:  2010-07-21       Impact factor: 2.303

Review 5.  From single cells to deep phenotypes in cancer.

Authors:  Sean C Bendall; Garry P Nolan
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

6.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

7.  Overall survival and PD-L1 expression in metastasized malignant melanoma.

Authors:  Jules Gadiot; Anna I Hooijkaas; Andrew D M Kaiser; Harm van Tinteren; Hester van Boven; Christian Blank
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

8.  CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

Authors:  Chrysoula I Liakou; Ashish Kamat; Derek Ng Tang; Hong Chen; Jingjing Sun; Patricia Troncoso; Christopher Logothetis; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

9.  Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade.

Authors:  Willemijn B Breunis; Eduardo Tarazona-Santos; Renee Chen; Maureen Kiley; Steven A Rosenberg; Stephen J Chanock
Journal:  J Immunother       Date:  2008 Jul-Aug       Impact factor: 4.456

10.  A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Authors:  Omid Hamid; Henrik Schmidt; Aviram Nissan; Laura Ridolfi; Steinar Aamdal; Johan Hansson; Michele Guida; David M Hyams; Henry Gómez; Lars Bastholt; Scott D Chasalow; David Berman
Journal:  J Transl Med       Date:  2011-11-28       Impact factor: 5.531

View more
  46 in total

1.  PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.

Authors:  Jan Budczies; Gunhild Mechtersheimer; Carsten Denkert; Frederick Klauschen; Sadaf S Mughal; Priya Chudasama; Michael Bockmayr; Korinna Jöhrens; Volker Endris; Amelie Lier; Felix Lasitschka; Roland Penzel; Manfred Dietel; Benedikt Brors; Stefan Gröschel; Hanno Glimm; Peter Schirmacher; Marcus Renner; Stefan Fröhling; Albrecht Stenzinger
Journal:  Oncoimmunology       Date:  2017-01-27       Impact factor: 8.110

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 3.  Informatics for cancer immunotherapy.

Authors:  J Hammerbacher; A Snyder
Journal:  Ann Oncol       Date:  2017-12-01       Impact factor: 32.976

4.  Detection of immune responses after immunotherapy in glioblastoma using PET and MRI.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Diana L Moughon; Anthony C Wang; Joey Orpilla; Caius Radu; Benjamin M Ellingson; Jason T Lee; Timothy Cloughesy; Michael E Phelps; Johannes Czernin; Linda M Liau; Robert M Prins
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-05       Impact factor: 11.205

Review 5.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

Review 6.  Interaction of molecular alterations with immune response in melanoma.

Authors:  Robert A Szczepaniak Sloane; Vancheswaran Gopalakrishnan; Sangeetha M Reddy; Xue Zhang; Alexandre Reuben; Jennifer A Wargo
Journal:  Cancer       Date:  2017-06-01       Impact factor: 6.860

7.  Quantifying spatiotemporal variability and noise in absolute microbiota abundances using replicate sampling.

Authors:  Brian W Ji; Ravi U Sheth; Purushottam D Dixit; Yiming Huang; Andrew Kaufman; Harris H Wang; Dennis Vitkup
Journal:  Nat Methods       Date:  2019-07-15       Impact factor: 28.547

8.  STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.

Authors:  Carminia M Della Corte; Triparna Sen; Carl M Gay; Kavya Ramkumar; Lixia Diao; Robert J Cardnell; Bertha Leticia Rodriguez; C Allison Stewart; Vassiliki A Papadimitrakopoulou; Laura Gibson; Jared J Fradette; Qi Wang; Youhong Fan; David H Peng; Marcelo V Negrao; Ignacio I Wistuba; Junya Fujimoto; Luisa M Solis Soto; Carmen Behrens; Ferdinandos Skoulidis; John V Heymach; Jing Wang; Don L Gibbons; Lauren A Byers
Journal:  J Thorac Oncol       Date:  2020-02-15       Impact factor: 15.609

Review 9.  Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?

Authors:  Geoffrey Alan Watson; Jeffrey Doi; Aaron Richard Hansen; Anna Spreafico
Journal:  Br J Clin Pharmacol       Date:  2020-06-13       Impact factor: 4.335

Review 10.  Emerging trends in the immunotherapy of pancreatic cancer.

Authors:  Kasturi Banerjee; Sushil Kumar; Kathleen A Ross; Shailendra Gautam; Brittany Poelaert; Mohd Wasim Nasser; Abhijit Aithal; Rakesh Bhatia; Michael J Wannemuehler; Balaji Narasimhan; Joyce C Solheim; Surinder K Batra; Maneesh Jain
Journal:  Cancer Lett       Date:  2017-12-12       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.